FMS — FRESENIUS MEDICAL CARE AG
Public company
Sign in to save3 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
About FRESENIUS MEDICAL CARE AG (FMS)
FRESENIUS MEDICAL CARE AG (FMS) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Izzy Englander (Millennium Management), valued at $37M. Across recent filings, tracked investors recorded 2 new positions, 0 increased, 0 reduced, and 0 exited. All data sourced from SEC 13F filings.
Tracked investors reporting FMS
- Izzy EnglanderMar 31, 2026Millennium ManagementShares1.6MValue$37M% Portfolio0.02%
- Steve CohenMar 31, 2026Point72 Asset ManagementShares509.9KValue$11.5M% Portfolio0.01%
- Ken GriffinMar 31, 2026Citadel AdvisorsShares102.9KValue$2.3M% Portfolio0.00%
Recent activity
- New$27MFeb 17, 2026
- New$11.5MMay 15, 2026
Frequently asked questions
- How many institutional investors hold FMS?
- 3 tracked institutional investors disclosed a position in FMS (FRESENIUS MEDICAL CARE AG) in their most recent 13F filing.
- Who is the largest institutional holder of FMS?
- Izzy Englander, Millennium Management, holds the largest disclosed position in FMS, valued at $37M.
- Did institutional ownership of FMS increase or decrease?
- Across recent 13F filings, tracked investors recorded 2 new positions, 0 increased, 0 reduced, and 0 fully exited FMS.
- Where does this FMS ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.